ReviewHandbook of experimental pharmacology2026
Cardiovascular Dysfunction in Type 2 Diabetes: The Role of MicroRNAs.
Review in Handbook of experimental pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes (T2D) is a major health concern that leads to multiple chronic complications. Among these, cardiovascular dysfunction is a prominent contributor to the morbidity and mortality associated with T2D. MicroRNAs (miRNAs) are non-coding RNAs that regulate protein synthesis by activating or suppressing target genes. Recently, their role in the cardiovascular complications of T2D has attracted significant attention. Several miRNAs have emerged as key regulators. In diabetic hearts, miRNAs such as miR-133, miR-1, miR-34a, and miR-21 influence critical processes, including hypertrophy, fibrosis, oxidative stress, and cell death. miR-126, in particular, is one of the most studied miRNAs in the context of vascular function in T2D, playing a crucial role in endothelial function, vascular integrity, and angiogenesis. Evidence to date suggests that altered levels of specific miRNAs contribute to cardiovascular dysfunction in T2D, making them potential therapeutic targets for preventing or treating these complications. In this chapter, we aim to discuss the impact of miRNAs on the cardiovascular system in T2D.
Indexed as
Identifiers
42113222What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.